摘要
为探讨耐高压双腔PICC在结直肠癌患者mFOLFOX6方案化疗中的应用效果,选择2018年6月至2019年6月于我院就诊的100例结直肠癌患者为研究对象,采用随机数字表法将其分为观察组和对照组,各50例。2组患者均采用mFOLFOX6方案化疗(奥沙利铂+醛氢叶酸+5-氟尿嘧啶),观察组采用耐高压双腔PICC途径给药,对照组采用三向瓣膜单腔PICC途径给药,比较2组患者留置PICC穿刺点处渗血、机械性静脉炎发生情况及患者满意率。结果显示,观察组患者PICC穿刺点渗血发生率(12.00%)明显低于对照组(30.00%),P<0.05;2组患者均未发生Ⅳ级机械性静脉炎,观察组机械性静脉炎发生率(12.00%)明显低于对照组(34.00%),P<0.05;观察组患者满意率(96.00%)明显高于对照组(80.00%),P<0.05。结果表明,应用耐高压双腔PICC对结直肠癌患者化疗,可降低穿刺点渗血、机械性静脉炎发生率,提高患者满意度。
This study was to investigate the application efficacy of high-pressure-resisting double-cavity PICC(simply named double-cavity PICC)in mFOLFOX6schema of chemotherapy for colorectal cancer,randomly divided 100patients with colorectal carcinoma treated in author's hospital(2018-06-2019-06)into observation group and control group,50cases per group;both groups'patients were all given with mFOLFOX6schema(oxaliplatin+lencorin+5-FU),merely in observation group via double-cavity PICC,but in control group via triple-direction valve mono-cavity PICC(simply named mono-cavity PICC);then,compared both groups'patient's satisfactory degree,as well as complication(indwelling PICC puncture site staxis,and mechanical phlebitis).As results,the staxis incidence of observation group was significantly lower than that of control group(12.00%vs 30.00%,P<0.05);noⅣgrade of mechanical phlebitis were found in both groups,but mechanical phlebitis incidence of observation group was significantly lower than that of control group(12.00%vs 34.00%,P<0.05);the satisfactory degree of observation group was significantly higher than that of control group(96.00%vs 80.00%,P<0.05).Results show that double-cavity PICC is superior to mono-cavity PICC in more lower incidence of complications,and higher satisfactory degree.
作者
曹小丽
CAO Xiao-li(Dept.of General Medicine,the Central Hospital of Nanyang City,Nanyang,Henan 473000)
出处
《中国肛肠病杂志》
2020年第8期50-52,共3页
Chinese Journal of Coloproctology
关键词
结直肠癌
化疗
耐高压双腔PICC
三向瓣膜单腔PICC
机械性静脉炎
Colorectal cancer
Chemotherapy
High-pressure-resisting double-cavity PICC
Triple-direction mono-cavity PICC
Mechanical phlebitis
